Patents by Inventor Alyson M. Wilbanks

Alyson M. Wilbanks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof
    Patent number: 7208152
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR, HBMBU14 and CXCR6) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5 and CXCL16) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine SExCkine (also referred to as chemokine alpha-5) and inhibit binding of SExCkine to receptor (e.g., Bonzo). The invention also relates to targeting molecules which contain a first binding moiety which binds to mammalian Bonzo and a second binding moiety which binds to a molecule expressed on the surface of a target cell.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: April 24, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks, Lijun Wu
  • Antibodies and ligands for “Bonzo” chemokine receptor
    Patent number: 7038018
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR, HBMBU14 and CXCR6) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5 and CXCL16) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The invention further relates to a method of modulating a function of Bonzo, and to the use of the antibodies, antigen-binding fragments, targeting molecules and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: May 2, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks, Lijun Wu
  • Novel antibodies and ligands for "Bonzo" chemokine receptor
    Publication number: 20030165995
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR, HBMBU14 and CXCR6) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5 and CXCL16) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine SExCkine (also referred to as chemokine alpha-5) and inhibit binding of SExCkine to receptor (e.g., Bonzo). The invention also relates to targeting molecules which contain a first binding moiety which binds to mammalian Bonzo and a second binding moiety which binds to a molecule expressed on the surface of a target cell.
    Type: Application
    Filed: June 17, 2002
    Publication date: September 4, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks, Lijun Wu
  • Novel antibodies and ligands for "Bonzo" chemokine receptor
    Publication number: 20020090657
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR and HBMBU14) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine SExCkine (also referred to as chemokine alpha-5) and inhibit binding of SExCkine to receptor (e.g., Bonzo). The invention also relates to targeting molecules which contain a first binding moiety which binds to mammalian Bonzo and a second binding moiety which binds to a molecule expressed on the surface of a target cell.
    Type: Application
    Filed: August 27, 2001
    Publication date: July 11, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks, Lijun Wu
  • Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor
    Patent number: 6319675
    Abstract: The invention relates to a method of detecting and/or identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand and/or modulate a function of Bonzo.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: November 20, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks, Lijun Wu